broggini massimo
机构: Istituto Mario Negri
每年引用次数
引用次数
引用: 12,180
H-指数: 63
I10-指数 : 195
出版物: 401
Probing an Allosteric Pocket of CDK2 with Small Molecules
Michael S Christodoulou , Fabiana Caporuscio , Valentina Restelli , Luca Carlino
ChemMedChem 12 ( 1) 33 -41
11
2017
Inside Cover: Probing an Allosteric Pocket of CDK2 with Small Molecules (ChemMedChem 1/2017)
Michael S Christodoulou , Fabiana Caporuscio , Valentina Restelli , Luca Carlino
ChemMedChem 12 ( 1) 2 -2
2017
Structure-Activity Relationships of Hexahydrocyclopenta[c]quinoline Derivatives as Allosteric Inhibitors of CDK2 and EGFR.
Luca Carlino , Michael S Christodoulou , Valentina Restelli , Fabiana Caporuscio
ChemMedChem 13 ( 24) 2627 -2634
9
2018
Role of Cetuximab in the Treatment of Patients With NSCLC: Are We Throwing Out the Baby With the Bath Water?
Irene Floriani , Marina Chiara Garassino , Massimo Broggini , Silvio Veronese
Journal of Clinical Oncology 28 ( 27)
1
2010
Cisplatinum and taxol induce different patterns of p53 phosphorylation.
Giovanna Damia , Laura Filiberti , Faina Vikhanskaya , Laura Carrassa
Neoplasia 3 ( 1) 10 -16
75
2001
Driving p53 response to Bax activation greatly enhances sensitivity to taxol by inducing massive apoptosis.
Paola De Feudis , Sara Vignati , Cosmo Rossi , Tatiana Mincioni
Neoplasia 2 ( 3) 202 -207
24
2000
Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts
Francesca Ricci , Federica Guffanti , Giovanna Damia , Massimo Broggini
Molecular Cancer 16 ( 1) 97 -97
10
2017
The 5′UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs
Eliana Rulli , Federica Guffanti , Elisa Caiola , Monica Ganzinelli
Scientific Reports 6 ( 1) 39217 -39217
2016
Diferential adriamycin® istribution to blood components
Tina Colombo , Massimo Broggini , Silvio Garattini , Maria Grazia Donelli
European Journal of Drug Metabolism and Pharmacokinetics 6 ( 2) 115 -122
11
1981
Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells
Laura Brunelli , Elisa Caiola , Mirko Marabese , Massimo Broggini
Oncotarget 5 ( 13) 4722 -4731
49
2014
p73: a chiaroscuro gene in cancer.
Mirko Marabese , Faina Vikhanskaya , Massimo Broggini
European Journal of Cancer 43 ( 9) 1361 -1372
39
2007
Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer
Mirko Marabese , Sergio Marchini , Eleonora Marrazzo , Pietro Mariani
European Journal of Cancer 44 ( 1) 131 -141
31
2008
Improving the selectivity of cancer treatments by interfering with cell response pathways.
Giovanna Damia , Massimo Broggini
European Journal of Cancer 40 ( 17) 2550 -2559
22
2004
In vivo effect of copper status on cisplatin-induced nephrotoxicity
Ludmila V Puchkova , Alexey N Skvortsov , Paolo Rusconi , Ekaterina Yu Ilyechova
Biometals 29 ( 5) 841 -849
4
2016
COMBINATION OF PI3K/mTOR INHIBITORS: ANTITUMOR ACTIVITY AND MOLECULAR CORRELATES
Marco Mazzoletti , Francesca Bortolin , Laura Brunelli , Roberta Pastorelli
Cancer Research 71 ( 13) 4573 -4584
64
2011
Brostallicin: a new concept in minor groove DNA binder development.
Massimo Broggini , Sergio Marchini , Erminia Fontana , Donatella Moneta
Anti-Cancer Drugs 15 ( 1) 1 -6
24
2004
Horseradish peroxidase/hydrogen peroxide-catalyzed oxidation of VP16-213. Identification of a new metabolite.
Massimo Broggini , Cosmo Rossi , Emilio Benfenati , Maurizio D'Incalci
Chemico-Biological Interactions 55 215 -224
10
1985
CRISP-R/Cas9 Mediated Deletion of Copper Transport Genes CTR1 and DMT1 in NSCLC Cell Line H1299. Biological and Pharmacological Consequences.
Ekaterina Y Ilyechova , Elisa Bonaldi , Iurii A Orlov , Ekaterina A Skomorokhova
Cells 8 ( 4) 322
3
2019
CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers
Francesco Bertoni , Anna Maria Codegoni , Daniela Furlan , Maria Grazia Tibiletti
Genes, Chromosomes and Cancer 26 ( 2) 176 -180
110
1999
Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR).
Monica Ganzinelli , Eliana Rulli , Elisa Caiola , Marina Chiara Garassino
Scientific Reports 5 ( 1) 16331 -16331
8
2015